- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01758705
Post Marketing Observational Study on Venezuelan Patients With Psoriasis
November 26, 2016 updated by: AbbVie (prior sponsor, Abbott)
Observational Study; Clinical Effectiveness and Impact on Patient Reported Outcomes in Venezuelan Patients With Psoriasis After 16 Weeks of ADA Therapy
The aim of this study is to obtain Venezuelan data of clinical effectiveness, impact in the HRQoL, work productivity and activity impairment in patients with psoriasis using adalimumab.
Study Overview
Status
Withdrawn
Conditions
Study Type
Observational
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Subjects male or female with moderate to severe chronic plaque psoriasis with or without psoriatic arthritis.
Patients with history of psoriatic arthritis or articular symptoms must be evaluated by a Rheumatologist.
Description
Inclusion Criteria:
- Subjects with moderate to severe chronic plaque psoriasis, with or without psoriatic arthritis, who have the indication for adalimumab because they need systemic therapy or because they have had failure to phototherapy, or to other systemic or topical treatments
- Subjects that are not receiving biologic therapy in the last 12 weeks or classical therapy in the past 4 weeks and/or phototherapy in the last 2 weeks. Topical therapy will be allowed, to a constant dose and will not be used within 24 hours prior to the visit
- Patients under previous treatment with any experimental drug will have a minimum washout period of five half-lives
- Subjects must be capable to understand and willing to give a written informed consent form to release information and to comply with the requirements of the study protocol
Exclusion Criteria:
- Subjects should not be enrolled if they cannot be treated in accordance with the local product label approved in Venezuela
- Subjects enrolled into another study or under treatment with an investigational product
- History of viral hepatitis B infection or HIV
- History of neurologic symptoms suggestive of central nervous system demyelinating disease
- History of cancer or lymphoproliferative disease (other than successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix)
- Active TB infection before initiating adalimumab treatment or latent TB infection not able to complete prophylactic treatment
- Pregnant or lactating female. Pregnancy will be tested before entering the study in fertile women. Women in fertile age must be advised by the physician, to use a clinically accepted contraceptive method (contraceptive pills, IUDs, barrier devices as condoms or abstinence)
- History of congestive heart failure (CHF)
- Any another condition that according to the criteria of the participating investigator represents an obstacle for study conduction and / or subjects to an unacceptable risks
- Subjects with active infection including chronic or localized infections until infections are controlled
- History of sensitive to latex or other component of the syringe
- Subjects who requires concomitant phototherapy and systemic therapy during adalimumab therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Cohort 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in PASI 75 (Psoriasis Area and Severity Index score) Response Rate
Time Frame: From Week 0 to Week 16
|
From Week 0 to Week 16
|
|
Change in Percentage of patients with clinical difference in DLQI (Dermatology Life Quality Index) score
Time Frame: From Week 0 to Week 16
|
Clinical difference is defined by a minimal important difference (MID) in DLQI score between 2.3-5 at 16 weeks
|
From Week 0 to Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change of PASI score
Time Frame: From week 0 to week 16
|
From week 0 to week 16
|
|
Mean change of DLQI score
Time Frame: From week 0 to week 16
|
From week 0 to week 16
|
|
Changes in Psoriatic Arthritis Response Criteria (PsARC) score
Time Frame: From week 0 to week 16
|
From week 0 to week 16
|
|
Mean change of Hospital Anxiety and Depression Score (HADS)
Time Frame: From week 0 to week 16
|
From week 0 to week 16
|
|
Mean change en Work Productivity and Activity Impairment (WPAI)-Psoriasis score
Time Frame: From week 0 to week 16
|
From week 0 to week 16
|
|
Percentage of subjects with Serious Adverse Events (SAEs)
Time Frame: Up to week 16
|
Occurrence of SAEs including tuberculosis, other opportunistic infections and cancer
|
Up to week 16
|
Discontinuation of adalimumab for any reason.
Time Frame: Up to week 16
|
Up to week 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Natali Serra-Bonett, MD, Abbott
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (Actual)
March 1, 2016
Study Completion (Actual)
March 1, 2016
Study Registration Dates
First Submitted
December 26, 2012
First Submitted That Met QC Criteria
December 26, 2012
First Posted (Estimate)
January 1, 2013
Study Record Updates
Last Update Posted (Estimate)
November 29, 2016
Last Update Submitted That Met QC Criteria
November 26, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P13-709
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate to Severe Chronic Plaque Psoriasis
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey, United Kingdom
-
UCB Biopharma SRLActive, not recruitingModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisChina
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Canada
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
-
CelltrionRecruitingModerate to Severe Chronic Plaque PsoriasisEstonia
-
Biocon Biologics UK LtdActive, not recruitingModerate to Severe Chronic Plaque PsoriasisUnited States
-
Astellas Pharma IncBiogenCompleted
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingModerate to Severe Chronic Plaque PsoriasisChina
-
Sun Pharmaceutical Industries LimitedRecruitingModerate-to-severe Chronic Plaque PsoriasisUnited States, Hungary, India, Poland, Slovakia, Spain